University Vita-Salute San Raffaele, Department of Clinical Neurosciences , Milan , Italy
Expert Opin Drug Saf. 2013 Nov;12(6):873-80. doi: 10.1517/14740338.2013.828690. Epub 2013 Sep 16.
Agomelatine is a relatively new antidepressant with a mechanism of action that is different from other antidepressants: it is a melatonergic agonist and a 5-HT2C antagonist. It is an effective treatment for depression, with relatively mild side effects. It may be a valuable pharmacological alternative in the clinical approach on depression.
The literature about agomelatine has been comprehensively reviewed. Agomelatine's efficacy, safety and tolerability are reviewed based on the studies undertaken in patients with major depressive disorder (MDD) and bipolar disorder (BPD).
Agomelatine has shown an antidepressant effect in preclinical models, and the results of a large-scale clinical trial program, conducted in MDD, indicate both an antidepressant activity and a favorable tolerability profile. Agomelatine has no discontinuation syndrome, sexual discomfort is rare, and it is generally weigh neutral. The drug appears to be relatively safe in case of overdose. However, some cases of elevated hepatic transaminases are reported during treatment. As agomelatine has a mechanism of action that differs from other agents, it may represent a valuable additional treatment option in those patients who do not respond fully or who do not tolerate the side effects of other antidepressants.
阿戈美拉汀是一种相对较新的抗抑郁药，其作用机制有别于其他抗抑郁药：它既是褪黑素激动剂，也是 5-HT2C 拮抗剂。它是一种有效的抗抑郁治疗药物，副作用相对较轻。它可能是临床治疗抑郁症的一种有价值的药理学选择。
对阿戈美拉汀的文献进行了全面回顾。根据在重度抑郁症（MDD）和双相情感障碍（BPD）患者中进行的研究，评估了阿戈美拉汀的疗效、安全性和耐受性。
阿戈美拉汀在临床前模型中显示出抗抑郁作用，一项大规模临床试验计划的结果表明，该药具有抗抑郁活性和良好的耐受性。阿戈美拉汀没有停药综合征，性不适罕见，一般对体重无影响。药物过量时似乎相对安全。然而，在治疗过程中报告了一些肝转氨酶升高的病例。由于阿戈美拉汀的作用机制与其他药物不同，因此对于那些对其他抗抑郁药反应不完全或不能耐受其副作用的患者，它可能是一种有价值的额外治疗选择。
